Investors & Media

Search

Dosing Underway for Phase 1 Parkinson Trial of GBA1-Targeting Agent GT-02287

	About Us Science & Technology Pipeline Investors & Media Contact Us
©2023 Gain Therapeutics, Inc.	Cookie Policy \| Privacy PolicyFollow Us	©2020 Gain Therapeutics, Inc.

	About Us Science & Technology Pipeline Newsroom Contact Us Cookie Policy \| Privacy Policy
Follow Us	©2023 Gain Therapeutics, Inc.